» Articles » PMID: 27620866

Novel Mutations in Quinolone Resistance-determining Regions of GyrA, GyrB, ParC and ParE in Shigella Flexneri Clinical Isolates from Eastern Chinese Populations Between 2001 and 2011

Overview
Publisher Springer
Date 2016 Sep 14
PMID 27620866
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to evaluate the prevalence of fluoroquinolone resistance and mechanisms of selected fluoroquinolone resistance in Shigella flexneri isolates. A total of 624 S. flexneri strains isolated between 2001 and 2011 in Jiangsu Province of China were analysed for their fluoroquinolone susceptibility. The quinolone resistance-determining region of gyrA, gyrB, parC and parE were amplified and sequenced. In general, 90.5 % of S. flexneri exhibited resistance to nalidixic acid. The mean norfloxacin resistance rate was 22.4 % during the 11 years from 2001 to 2011 (6.4 % from 2001 to 2005 and 36.8 % from 2006 to 2011). Sequencing of gyrA, gyrB, parC and parE genes of all S. flexneri isolates showed that the mutation rate was as high as 93.9 %. In addition, 91.8 % and 92.3 % of S. flexneri harboured mutations in gyrA and parC, respectively. About 35.2 % of S. flexneri isolates susceptible to nalidixic acid contained mutations. Meanwhile, mutations were detected in 91.2 % of norfloxacin-susceptible strains, and almost all S. flexneri isolates resistant to fluoroquinolone contained mutations. To the best of our knowledge, this is the first study reporting the occurrence of point mutations Asn57Lys and His80Pro in gyrA and Ala85Thr, Asp111His and Ser129Pro in parC. Emerging fluoroquinolone resistance with a significantly high mutation rate of the gyrA and parC genes in S. flexneri in Jiangsu Province deserves attention, and monitoring antibiotic susceptibility is important for the effective management of S. flexneri infections.

Citing Articles

Concordance between Genotypic and Phenotypic Drug-Resistant Profiles of Isolates from Taiyuan City, Shanxi Province, China, 2005 to 2016.

Kong M, Liu C, Xu Y, Wang J, Jin D Microbiol Spectr. 2023; 11(3):e0011923.

PMID: 37249442 PMC: 10269460. DOI: 10.1128/spectrum.00119-23.


Prevalence of fluoroquinolone resistance and mutations in the gyrA, parC and parE genes of Riemerella anatipestifer isolated from ducks in China.

Zhu D, Zheng M, Xu J, Wang M, Jia R, Chen S BMC Microbiol. 2019; 19(1):271.

PMID: 31795952 PMC: 6892153. DOI: 10.1186/s12866-019-1659-4.


: Antibiotic-Resistance Mechanisms And New Horizons For Treatment.

Ranjbar R, Farahani A Infect Drug Resist. 2019; 12:3137-3167.

PMID: 31632102 PMC: 6789722. DOI: 10.2147/IDR.S219755.


In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Jean S, Lu M, Shi Z, Tseng S, Wu T, Lu P Infect Drug Resist. 2018; 11:1983-1992.

PMID: 30464540 PMC: 6208934. DOI: 10.2147/IDR.S175679.


Two novel mutations in among isolated from Jiangsu Province of China, 2016.

Xue C, Cai J, Kang H, Chen Y, Wang K, Qian H Ann Transl Med. 2018; 6(15):306.

PMID: 30211194 PMC: 6123205. DOI: 10.21037/atm.2018.07.11.


References
1.
Poole K . Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005; 56(1):20-51. DOI: 10.1093/jac/dki171. View

2.
Shen Y, Qian H, Gong J, Deng F, Dong C, Zhou L . High prevalence of antibiotic resistance and molecular characterization of integrons among Shigella isolates in Eastern China. Antimicrob Agents Chemother. 2013; 57(3):1549-51. PMC: 3591917. DOI: 10.1128/AAC.02102-12. View

3.
Yang H, Duan G, Zhu J, Zhang W, Xi Y, Fan Q . Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008. Int J Antimicrob Agents. 2013; 42(2):173-7. DOI: 10.1016/j.ijantimicag.2013.04.026. View

4.
Qiu S, Xu X, Yang C, Wang J, Liang B, Li P . Shift in serotype distribution of Shigella species in China, 2003-2013. Clin Microbiol Infect. 2015; 21(3):252.e5-8. DOI: 10.1016/j.cmi.2014.10.019. View

5.
Kotloff K, Winickoff J, Ivanoff B, Clemens J, Swerdlow D, Sansonetti P . Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999; 77(8):651-66. PMC: 2557719. View